Formulating for the Future of Transplant Patient Therapy

Transplant Support

Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.

Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here Go to


Mar 1, 2017
Annual report 2016 Investor Call

Webcast Webcast

Feb 7, 2017
Annual General Meeting

PDF Minutes of General Meeting
 237.8 KB   Add to Briefcase
PDF Notice to Convene Annual General Meeting 2017
 205.6 KB   Add to Briefcase
PDF Registration Form with Proxy and Absentee Vote
 103.3 KB   Add to Briefcase
PDF Articles of Association
 617.0 KB   Add to Briefcase
PDF AGM 2017 Presentation
 944.8 KB   Add to Briefcase
HTML file Shareholder portal

Stock Information